Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

Armando Santoro, MD51 enrolled

Overview

The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.

DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.

Study Type

OBSERVATIONAL

Enrollment

Conditions

NON-SMALL-CELL LUNG CANCER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Availability of tumor tissue or blood samples. * Diagnosis of NSCLC * At least one treatment with EGFR-TKIs inhibitors Exclusion Criteria: * Other than NSCLC primary diagnosis * No treatment with EGFR-TKIs inhibitors * No archival tissue available

Locations (1)

Istituto Clinco Humanitas

Rozzano, Mialno, Italy

Outcomes

Primary Outcomes

to evaluate the presence of EGFR- and AKT-DNA polymorphisms.

Time frame: At the end of enrollment

Secondary Outcomes

to correlate the biological characteristics with clinical characteristics and survival data of patients.

Time frame: At the end of enrollment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.